![]() | |
Clinical data | |
---|---|
Other names | WIN-32729 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C22H31NO3 |
Molar mass | 357.494 g·mol−1 |
3D model ( JSmol) | |
| |
|
Epostane ( INN, USAN, BAN) (developmental code name WIN-32729) is an inhibitor of 3β-hydroxysteroid dehydrogenase (3β-HSD) that was developed as a contraceptive, abortifacient, and oxytocic drug but was never marketed. [1] [2] [3] By inhibiting 3β-HSD, epostane blocks the biosynthesis of progesterone from pregnenolone (and also the conversion of dehydroepiandrosterone to androstenedione), thereby functioning as an antiprogestogen and terminating pregnancy. [1] The drug was trialed and in a study was found to be slightly more effective at inducing abortion relative to mifepristone. [4]